Ardelyx (NASDAQ:ARDX – Get Free Report) and Nanobiotix (NASDAQ:NBTX – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk.
Insider & Institutional Ownership
58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 5.3% of Ardelyx shares are owned by insiders. Comparatively, 3.5% of Nanobiotix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Volatility and Risk
Ardelyx has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ardelyx | 2 | 0 | 9 | 1 | 2.75 |
| Nanobiotix | 1 | 1 | 4 | 0 | 2.50 |
Ardelyx presently has a consensus target price of $15.73, indicating a potential upside of 212.67%. Nanobiotix has a consensus target price of $37.33, indicating a potential downside of 5.96%. Given Ardelyx’s stronger consensus rating and higher probable upside, analysts plainly believe Ardelyx is more favorable than Nanobiotix.
Profitability
This table compares Ardelyx and Nanobiotix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ardelyx | -13.58% | -38.11% | -11.85% |
| Nanobiotix | N/A | N/A | N/A |
Valuation & Earnings
This table compares Ardelyx and Nanobiotix”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ardelyx | $407.32 million | 3.05 | -$61.60 million | ($0.23) | -21.87 |
| Nanobiotix | $36.87 million | 54.51 | -$27.11 million | N/A | N/A |
Nanobiotix has lower revenue, but higher earnings than Ardelyx.
Summary
Ardelyx beats Nanobiotix on 7 of the 13 factors compared between the two stocks.
About Ardelyx
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
About Nanobiotix
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.
